SLC22A1 and B-cell chronic lymphocytic leukemia: Bendamustine, a drug currently used in front line treatment of Chronic Lymphocytic Leukemia (CLL) also appears to be a hOCT1 substrate and genetic heterogeneity in CLL patients appears to account for a subset of cases with altered drug sensitivity (Arimany-Nardi et al., 2015b).